MNKD Stock Balance Sheets

MannKind Quarterly Balance Sheets Chart

Quarterly

Annual

Goodwill

Account Receivables

Cash and Cash Eq

Account Payables

Inventory

MannKind Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30

assets
current assets:
cash and cash equivalents	57,006,000	47,312,000	46,339,000	62,373,000	96,643,000	193,272,000	238,480,000	83,016,000	86,184,000	85,869,000	69,767,000	54,308,000	35,507,000	67,243,000	124,184,000	51,740,000	62,522,000	247,833,000	67,005,000	52,398,000	63,222,000	38,868,000	29,906,000	30,173,000	7,968,000	34,530,000	71,157,000	10,446,000	26,178,000	26,706,000	43,946,000	20,092,000	43,384,000	47,978,000	22,895,000	35,530,000	63,733,000	27,653,000	59,074,000	32,928,000	107,187,000	120,844,000	120,841,000	172,465,000	41,214,000	35,759,000	70,790,000	93,803,000	28,529,000	28,005,000	61,840,000	1,765,000	31,639,000	56,355,000	2,681,000	22,786,000	24,770,000	46,912,000	66,061,000	97,928,000	28,358,000	29,052,000	30,019,000	53,918,000	31,328,000	27,114,000	27,648,000	31,582,000	180,454,000	269,079,000	368,285,000	152,298,000	216,429,000	262,753,000	319,555,000	43,086,000	27,056,000	45,889,000	56,037,000	69,238,000	19,552,000	22,089,000	78,987,000	103,871,000	37,373,000
short-term investments	121,979,000	134,229,000	150,917,000	189,215,000	151,118,000	107,457,000	56,619,000	58,000,000	58,163,000	80,273,000	101,079,000	110,738,000	118,649,000	95,203,000	79,932,000	87,312,000	99,970,000	28,962,000					19,978,000	19,885,000	24,909,000	24,764,000
accounts receivable	27,142,000	28,900,000	11,804,000	18,184,000	23,346,000	19,912,000	14,901,000	21,822,000	27,789,000	19,714,000	16,801,000	23,493,000	15,030,000	9,823,000	4,994,000	9,445,000	6,305,000	3,573,000	4,218,000	4,135,000	3,366,000	5,032,000	3,513,000	4,093,000	4,974,000	3,759,000	4,017,000	2,752,000	2,848,000	1,550,000	2,789,000	1,804,000	1,312,000	438,000	302,000	3,137,000
inventory	28,491,000	28,892,000	27,886,000	26,663,000	24,753,000	26,442,000	28,545,000	27,117,000	25,290,000	21,998,000	21,772,000	18,273,000	20,573,000	8,044,000	7,152,000	7,482,000	7,482,000	5,050,000	4,973,000	4,881,000	3,823,000	3,231,000	4,155,000	3,692,000	3,963,000	3,720,000	3,597,000	2,785,000	3,676,000	3,891,000	2,657,000	3,129,000	3,172,000	3,698,000	2,331,000	5,124,000	2,866,000			23,402,000	19,816,000	16,789,000	9,670,000
prepaid expenses and other current assets	44,409,000	34,404,000	31,360,000	31,229,000	30,080,000	36,019,000	34,848,000	35,620,000	32,807,000	15,445,000	25,477,000	11,569,000	3,717,000	3,952,000	3,482,000	3,227,000	3,624,000	2,766,000	3,122,000	4,616,000	1,856,000	1,901,000	2,889,000	3,584,000	2,704,000	2,392,000	2,556,000	3,015,000	2,570,000	2,354,000	3,010,000	3,061,000	2,563,000	3,508,000	4,364,000	4,534,000	1,423,000	2,807,000	4,018,000	13,227,000	14,076,000	16,375,000	20,206,000	20,253,000	3,696,000	3,640,000	5,485,000	5,228,000	3,183,000	3,830,000	4,520,000	21,082,000	18,356,000	3,004,000	2,625,000	2,960,000	1,593,000	2,479,000	2,849,000	3,309,000	2,451,000	3,217,000	3,672,000	5,247,000	4,533,000	4,907,000	5,983,000	7,709,000	7,253,000	8,004,000	9,596,000	11,876,000	10,664,000	13,714,000	10,650,000	11,702,000	6,952,000	5,907,000	3,044,000	3,451,000	2,457,000	3,027,000	3,265,000	2,046,000	2,653,000
total current assets	279,027,000	273,737,000	268,306,000	327,664,000	325,940,000	383,102,000	373,393,000	225,575,000	230,233,000	223,299,000	234,896,000	218,381,000	193,476,000	184,265,000	219,744,000	159,206,000	179,903,000	288,342,000	79,476,000	66,346,000	72,583,000	49,348,000	60,757,000	61,743,000	49,834,000	69,692,000	81,854,000	19,525,000	35,799,000	35,028,000	57,216,000	28,629,000	50,931,000	56,094,000	77,488,000	48,604,000	90,764,000	44,143,000	76,654,000	71,236,000	145,827,000	158,290,000	201,153,000	193,521,000	44,910,000	39,399,000	76,275,000	99,329,000	32,162,000	32,285,000	66,810,000	23,197,000	50,345,000	59,709,000	5,821,000	27,024,000	26,860,000	50,614,000	73,954,000	102,028,000	33,223,000	34,757,000	37,666,000	63,314,000	38,500,000	35,136,000	53,975,000	102,942,000	187,707,000	277,083,000	378,712,000	219,220,000	298,610,000	383,209,000	449,547,000	62,713,000	58,851,000	109,540,000	149,872,000	187,106,000	45,448,000	72,159,000	95,881,000	112,417,000	43,913,000
restricted cash	741,000	739,000	737,000	735,000	732,000													158,000	158,000	316,000	316,000	316,000	316,000	316,000	5,316,000	527,000	527,000	527,000	527,000	527,000	4,409,000																																																	18,000	18,000	585,000	583,000	581,000	579,000
long-term investments	22,240,000	16,681,000	5,482,000	16,796,000	13,398,000	3,726,000	7,155,000	3,271,000	2,282,000	492,000	1,961,000	12,728,000	32,596,000	70,542,000	56,619,000	42,059,000	38,950,000	1,480,000
property and equipment	82,965,000	83,781,000	85,365,000	85,339,000	85,144,000	83,620,000	84,220,000	80,411,000	69,510,000	54,837,000	45,126,000	41,182,000	37,918,000	41,453,000	36,612,000	30,848,000	28,139,000	26,507,000	25,867,000	25,736,000	26,187,000	26,517,000	26,778,000	27,126,000	27,146,000	25,750,000	25,602,000	25,632,000	26,036,000	26,481,000	26,922,000
goodwill	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,998,000	2,428,000	3,067,000	2,900,000
other intangible assets	5,169,000	5,217,000	5,265,000	5,313,000
other assets	19,624,000	28,055,000	26,757,000	26,422,000	15,658,000	7,447,000	7,426,000	8,047,000	8,353,000	16,378,000	9,718,000	17,310,000	17,507,000	12,058,000	8,186,000	6,094,000	5,799,000	3,053,000	3,265,000	3,599,000	4,011,000	4,347,000	6,190,000				249,000	199,000	320,000	368,000	437,000	480,000	523,000	609,000	648,000	702,000	1,248,000	1,096,000	1,009,000	1,831,000	2,025,000	2,027,000	848,000	2,114,000	7,400,000	8,437,000	5,516,000	10,227,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	317,000	404,000	584,000	584,000	584,000	584,000	555,000	10,548,000	548,000	550,000	549,000	549,000	548,000	547,000	546,000	361,000	362,000	359,000	288,000	287,000	285,000	282,000	203,000	203,000	61,000	50,000	51,000
total assets	411,697,000	410,141,000	393,843,000	464,200,000	443,836,000	480,879,000	475,198,000	320,328,000	313,422,000	298,137,000	295,282,000	293,837,000	285,797,000	308,318,000	321,161,000	238,207,000	252,791,000	319,382,000	108,608,000	95,681,000	102,781,000	80,212,000	93,725,000	95,140,000	81,795,000	100,961,000	107,705,000	45,356,000	62,155,000	61,877,000	84,575,000	56,483,000	79,374,000	85,185,000	107,063,000	96,131,000	139,434,000			278,014,000	352,551,000
liabilities and stockholders' deficit
current liabilities:
accounts payable	10,257,000	5,041,000	6,792,000	6,444,000	9,556,000	7,149,000	9,580,000	16,754,000	17,127,000	13,889,000	11,052,000	9,871,000	7,823,000	8,702,000	6,956,000	9,528,000	7,486,000	6,706,000	5,582,000	5,797,000	5,821,000	6,731,000	4,789,000	11,664,000	7,533,000	6,978,000	5,379,000	5,815,000	9,237,000	4,976,000	6,984,000	5,283,000	6,541,000	1,519,000	3,263,000	5,093,000	2,849,000	582,000	15,599,000	4,444,000	5,190,000	3,302,000	7,394,000	17,389,000	5,086,000	3,638,000	3,860,000	7,786,000	5,419,000	3,604,000	4,555,000	3,166,000	5,817,000	2,661,000	4,624,000	1,598,000	1,600,000	5,360,000	3,294,000	6,372,000	2,365,000	8,766,000	6,519,000	8,801,000	11,171,000	14,222,000	15,630,000	19,992,000	30,084,000	24,399,000	35,463,000	36,738,000	5,653,000	10,123,000	10,715,000	6,673,000	2,586,000	4,008,000	3,547,000	5,407,000	4,621,000	5,095,000	3,477,000	1,429,000	1,840,000
accrued expenses and other current liabilities	30,915,000	40,103,000	40,293,000	37,386,000	40,952,000	42,291,000	42,036,000	32,098,000	36,833,000	32,995,000	35,553,000	30,350,000	33,184,000	27,131,000	27,419,000	20,829,000	22,406,000	27,586,000	19,707,000	15,814,000	14,706,000	18,326,000	15,904,000	14,298,000	16,452,000	18,064,000	15,022,000	13,434,000	14,075,000	15,930,000	12,449,000	12,492,000	9,076,000	10,657,000	7,937,000	14,164,000	10,252,000	8,077,000	7,929,000	14,081,000	13,930,000	12,381,000	26,206,000	27,269,000	20,579,000	15,006,000	21,634,000	21,553,000	26,984,000	26,379,000	25,777,000	48,598,000	49,624,000	31,746,000	20,736,000	15,715,000	19,958,000	19,035,000	14,840,000	19,193,000	19,824,000	17,534,000	22,334,000	19,624,000	27,718,000	25,937,000	37,842,000	36,087,000	31,874,000	31,048,000	32,095,000	36,109,000	52,758,000	45,730,000	34,244,000	31,034,000	24,548,000	20,249,000	17,818,000	13,553,000	11,567,000	7,618,000	8,194,000	6,382,000	4,835,000
senior convertible notes – current	36,166,000	36,109,000																																										99,120,000
liability for sale of future royalties – current	13,344,000	12,802,000	12,283,000	11,755,000	12,149,000	10,537,000	9,756,000
financing liability – current	10,190,000	10,125,000	10,062,000	9,998,000	9,935,000	9,872,000	9,809,000	9,747,000	9,686,000	9,626,000
deferred revenue – current	10,954,000	11,757,000	12,407,000	6,518,000	7,420,000	7,601,000	9,085,000	3,670,000	3,489,000	2,316,000
total current liabilities	111,826,000	115,937,000	81,837,000	72,101,000	80,012,000	99,896,000	104,125,000	96,374,000	96,966,000	81,853,000	67,296,000	59,597,000	59,564,000	53,494,000	48,349,000	50,033,000	60,429,000	73,116,000	73,705,000	106,124,000	67,939,000	68,248,000	65,618,000	64,287,000	76,978,000	77,868,000	75,241,000	59,627,000	74,901,000	80,669,000	87,597,000	91,468,000	85,869,000	93,049,000	92,051,000	105,832,000	289,706,000	249,211,000	268,319,000	267,307,000	342,254,000	380,753,000	403,353,000	293,778,000	119,233,000	44,515,000	127,794,000	217,169,000	266,782,000	264,211,000	144,775,000	51,764,000	55,441,000	34,407,000	25,360,000	17,313,000	21,558,000	24,395,000	18,134,000	25,565,000	22,189,000	26,300,000	28,853,000	28,425,000	38,889,000	40,159,000	53,472,000	56,079,000	61,958,000	55,447,000	67,558,000	72,847,000	58,411,000	55,853,000	44,959,000	87,707,000	27,134,000	24,257,000	21,365,000	18,960,000	16,188,000	14,086,000	13,044,000	9,184,000	8,048,000
liability for sale of future royalties – long term	137,230,000	137,420,000	137,362,000	137,140,000	135,365,000	137,418,000	136,054,000
financing liability – long term	93,476,000	93,665,000	93,877,000	94,005,000	94,094,000	94,207,000	94,319,000	94,375,000	94,395,000	94,441,000
deferred revenue – long term	45,472,000	47,360,000	51,160,000	65,150,000	66,116,000	67,741,000	69,794,000	69,469,000	60,248,000	45,659,000
recognized loss on purchase commitments – long term	66,076,000	60,713,000	58,204,000	62,638,000	60,183,000	60,287,000	60,942,000	50,534,000	56,063,000	59,829,000
operating lease liability	10,656,000	11,141,000	11,645,000	12,167,000	3,272,000	3,645,000	3,925,000	4,289,000	4,646,000	4,879,000	5,343,000	5,666,000	5,928,000	826,000	1,040,000	798,000	564,000	869,000	1,202,000	1,523,000	1,843,000	2,155,000	2,514,000
milestone liabilities	2,003,000	2,523,000	2,523,000	2,813,000	2,813,000	3,452,000	3,452,000	3,772,000	3,772,000	4,524,000	4,524,000	4,524,000	4,524,000
senior convertible notes			36,051,000	227,941,000	227,577,000	227,214,000	226,851,000	226,487,000	226,124,000	225,761,000	225,397,000	225,034,000	224,670,000	224,307,000	223,944,000	223,580,000	223,217,000	222,855,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	7,437,000	19,031,000	19,065,000	19,099,000	19,133,000	19,161,000	24,368,000	24,411,000	27,657,000	27,649,000	27,642,000	27,635,000		27,623,000	27,618,000				99,593,000	99,355,000		98,889,000	98,662,000		114,897,000	114,744,000	114,593,000	114,443,000	211,673,000	211,184,000	210,946,000	210,642,000	210,308,000	209,979,000	209,655,000	209,335,000	209,023,000	113,030,000	112,897,000	112,765,000	112,635,000	112,506,000	112,378,000	112,253,000	112,128,000	112,004,000	111,882,000	111,761,000	111,641,000	111,523,000	111,406,000	111,267,000
total liabilities	466,739,000	468,759,000	472,659,000	674,126,000	669,616,000	710,849,000	721,366,000	572,107,000	573,909,000	553,533,000	545,820,000	531,514,000	532,853,000	540,382,000	530,510,000	422,895,000	436,342,000	493,004,000	289,027,000	282,101,000	282,491,000	278,262,000	284,251,000	279,846,000	277,794,000	288,965,000	282,787,000	250,797,000	268,774,000	285,085,000	299,307,000	307,498,000	300,617,000	283,910,000	290,656,000	334,818,000	506,011,000	466,736,000	476,741,000	402,583,000	468,026,000	457,053,000	468,209,000	427,496,000	282,683,000	207,017,000	289,359,000	455,330,000	364,786,000	362,002,000	361,993,000	486,579,000	484,767,000	528,806,000	513,205,000	504,824,000	473,740,000	458,253,000	462,788,000	486,588,000	377,219,000	344,197,000	306,618,000	291,060,000	286,395,000	242,537,000	195,725,000	168,207,000	173,962,000	167,329,000	179,343,000	184,512,000	169,958,000	167,283,000	156,250,000	87,731,000	27,158,000	24,281,000	21,394,000	18,996,000	16,231,000	14,134,000	13,120,000	9,242,000	8,178,000
commitments and contingencies
stockholders' deficit:
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2025 or december 31, 2024
common stock	3,063,000	3,039,000	3,029,000	2,753,000	2,740,000	2,703,000	2,700,000	2,695,000	2,682,000	2,643,000	2,638,000	2,632,000	2,573,000	2,524,000	2,515,000	2,502,000	2,496,000	2,491,000	2,421,000	2,309,000	2,289,000	2,131,000	2,118,000	2,064,000	1,894,000	1,878,000	1,870,000	1,594,000	1,456,000	1,260,000	1,192,000	1,047,000	1,046,000	958,000	4,784,000	4,784,000	4,777,000	4,290,000	4,287,000	4,182,000	4,121,000	4,090,000	4,061,000	4,055,000	3,964,000	3,869,000	3,697,000	3,100,000	3,012,000	2,894,000	2,860,000	1,998,000	1,993,000	1,678,000	1,315,000	1,313,000	1,309,000	1,307,000	1,278,000	1,234,000	1,137,000	1,134,000	1,130,000	1,128,000	1,036,000	1,020,000	1,020,000	1,017,000	1,016,000	1,014,000	1,014,000	736,000	735,000	734,000	734,000	499,000	496,000	496,000	503,000	501,000	328,000	327,000	327,000	327,000	200,000
additional paid-in capital	3,128,631,000	3,125,830,000	3,118,865,000	2,995,974,000	2,992,271,000	2,986,104,000	2,980,539,000	2,975,891,000	2,968,917,000	2,969,225,000	2,964,293,000	2,960,419,000	2,936,667,000	2,922,555,000	2,918,205,000	2,914,818,000	2,911,535,000	2,885,946,000	2,866,303,000	2,834,003,000	2,829,478,000	2,801,044,000	2,799,278,000	2,790,890,000	2,769,396,000	2,765,020,000	2,763,067,000	2,723,232,000	2,698,028,000	2,658,957,000	2,638,992,000	2,570,072,000	2,566,960,000	2,554,230,000	2,549,212,000	2,548,090,000	2,546,727,000	2,510,367,000	2,508,633,000	2,457,482,000	2,434,777,000	2,424,347,000	2,416,967,000	2,413,621,000	2,371,487,000	2,362,129,000	2,261,996,000	2,072,006,000	2,036,640,000	1,996,185,000	1,991,379,000	1,774,893,000	1,763,939,000	1,694,658,000	1,620,535,000	1,616,981,000	1,614,018,000	1,611,373,000	1,587,858,000	1,553,763,000	1,552,335,000	1,547,077,000	1,544,112,000	1,541,223,000	1,478,908,000		1,469,497,000	1,463,191,000	1,456,556,000	1,449,519,000	1,444,125,000	1,184,914,000	1,180,523,000	1,175,540,000	1,170,602,000	778,053,000	772,536,000	768,074,000	763,775,000	764,529,000	590,530,000	592,414,000	592,999,000	595,531,000	435,240,000
accumulated other comprehensive income	1,257,000	1,174,000	1,109,000	588,000				443,000	443,000																																		-14,000				-4,000				-6,000	-8,000	-9,000	-3,000	44,000	45,000	38,000	86,000	74,000			-272,000	-281,000	-107,000	-119,000	354,000	295,000													8,000	8,000	7,000
accumulated deficit	-3,187,993,000	-3,188,661,000	-3,201,819,000	-3,209,241,000	-3,220,791,000	-3,218,777,000	-3,229,407,000	-3,230,808,000	-3,232,529,000	-3,227,264,000	-3,217,469,000	-3,199,522,000	-3,185,090,000	-3,156,067,000	-3,130,069,000	-3,102,008,000	-3,097,582,000	-3,062,059,000	-3,049,143,000	-3,022,732,000	-3,011,477,000	-3,001,225,000	-2,991,903,000	-2,977,640,000	-2,967,270,000	-2,954,883,000	-2,940,000,000	-2,930,249,000	-2,906,085,000	-2,883,410,000	-2,854,898,000	-2,822,114,000	-2,789,228,000	-2,753,889,000	-2,737,565,000	-2,791,540,000	-2,918,060,000	-2,888,102,000	-2,863,229,000	-2,586,214,000	-2,554,353,000	-2,525,447,000	-2,494,784,000
total stockholders' deficit	-55,042,000	-58,618,000	-78,816,000	-209,926,000	-225,780,000	-229,970,000	-246,168,000	-251,779,000	-260,487,000	-255,396,000	-250,538,000	-237,677,000	-247,056,000	-232,064,000	-209,349,000	-184,688,000	-183,551,000	-173,622,000	-180,419,000	-186,420,000	-179,710,000	-198,050,000	-190,526,000	-184,706,000	-195,999,000	-188,004,000	-175,082,000	-205,441,000	-206,619,000	-223,208,000	-214,732,000	-251,015,000
total liabilities and stockholders' deficit	411,697,000	410,141,000	393,843,000	464,200,000	443,836,000	480,879,000	475,198,000	320,328,000	313,422,000	298,137,000	295,282,000	293,837,000	285,797,000	308,318,000	321,161,000	238,207,000	252,791,000	319,382,000	108,608,000	95,681,000	102,781,000	80,212,000	93,725,000	95,140,000	81,795,000	100,961,000	107,705,000	45,356,000	62,155,000	61,877,000	84,575,000	56,483,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2025 or december 31, 2024
recognized loss on purchase commitments – current						2,446,000	3,859,000	14,105,000	13,164,000	11,360,000
midcap credit facility – current						20,000,000	20,000,000	20,000,000	16,667,000	11,667,000
midcap credit facility – long term						8,105,000	13,019,000	17,921,000	22,811,000
mann group convertible note						8,829,000	8,829,000	8,829,000	8,829,000	8,829,000		8,829,000	8,829,000
accrued interest – mann group convertible note						55,000	56,000	57,000	55,000	54,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of december 31, 2024 or 2023
financing lease liability				171,000	184,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2024 or december 31, 2023
other intangible asset					1,033,000	1,053,000	1,073,000	1,093,000	1,113,000	1,133,000	1,153,000	1,169,000	1,400,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2024 or december 31, 2023
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2024 or december 31, 2023
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of december 31, 2023 and 2022
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2023 and december 31, 2022
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2023 and december 31, 2022
midcap credit facility										27,704,000	39,264,000	39,155,000	39,047,000	38,939,000		38,723,000	38,614,000	49,406,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2023 and december 31, 2022
accumulated other comprehensive loss												-1,206,000	-1,206,000	-1,076,000									-19,000	-20,000	-19,000	-19,000	-19,000	-18,000	-18,000	-15,000	-18,000	-20,000	-21,000	-24,000	-24,000	-21,000	-21,000	-19,000	-20,000	-19,000	-20,000	-21,000		-11,000	-4,000	-4,000		-9,000	-8,000	-8,000											-1,000
financing liability — current											9,565,000	9,525,000	9,470,000	9,410,000	6,977,000
deferred revenue — current											1,733,000	1,786,000	1,667,000	1,307,000	827,000	14,016,000	20,126,000	25,880,000	33,275,000	28,867,000	32,184,000	30,840,000	32,503,000
recognized loss on purchase commitments — current											9,393,000	8,065,000	7,420,000	6,944,000	6,170,000	5,660,000	5,538,000	8,274,000	11,080,000	10,267,000	9,841,000	7,250,000	7,394,000												5,093,000
promissory notes											8,829,000			18,425,000	18,425,000				63,027,000	70,025,000	70,024,000	70,022,000	70,020,000	70,019,000
accrued interest — promissory notes											55,000		86,000	520,000	404,000				4,150,000	5,854,000	4,538,000	3,259,000	2,002,000
financing liability — long term											94,512,000	94,484,000	94,447,000	93,463,000	93,525,000
recognized loss on purchase commitments — long term											62,916,000	62,173,000	65,996,000	72,400,000	76,659,000	79,653,000	83,179,000	80,797,000	84,208,000	84,529,000	81,027,000	82,987,000	84,639,000												95,942,000
deferred revenue — long term											37,684,000	31,996,000	29,762,000	26,116,000	19,543,000	1,552,000	1,589,000	1,626,000	1,662,000	1,699,000	4,860,000	1,772,000	8,344,000
deposits from customer														7,054,000	4,950,000	5,007,000	5,317,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2022 and 2021
accrued interest — promissory note												56,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2022 and december 31, 2021
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2022 and december 31, 2021
milestone rights liability														4,838,000	4,838,000	4,838,000	4,839,000	5,926,000	5,926,000	5,926,000	5,926,000	5,926,000	7,263,000	7,263,000	7,201,000	7,201,000	7,201,000	7,202,000	7,201,000	7,201,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2022 and december 31, 2021
paycheck protection program loan — current																			4,061,000
long-term midcap credit facility															38,833,000				49,335,000		39,304,000	38,893,000	38,851,000
2024 convertible notes
paycheck protection program loan — long term																			812,000	1,421,000	2,030,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2021 and 2020
ppp loan — current																	4,873,000	4,670,000
mann group promissory notes																18,425,000	18,425,000	53,453,000
accrued interest — mann group promissory notes																286,000	169,000	4,753,000
ppp loan — long term																		203,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2021 and december 31, 2020
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2021 and december 31, 2020
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2021 and december 31, 2020
short-term note payable																						5,101,000	5,028,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2020 and 2019
short-term notes payable																				45,379,000	5,387,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2020 and december 31, 2019
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2020 and december 31, 2019
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2020 and december 31, 2019
revenues:
net revenue — commercial product sales																						8,000,000	25,304,000												1,895,000
revenue — collaborations and services																						8,235,000	37,734,000
total revenues																						16,235,000	63,038,000	14,595,000	15,002,000	17,448,000	27,859,000	4,469,000	3,893,000	3,465,000	11,745,000	2,043,000	2,163,000	3,009,000
expenses:
cost of goods sold																						4,164,000	20,078,000	7,099,000	4,327,000	4,020,000	19,402,000	5,303,000	5,095,000	4,008,000	17,228,000	4,575,000	5,086,000	2,548,000	17,121,000	4,331,000
cost of revenue — collaborations and services																						3,362,000	7,901,000
research and development																						1,755,000	6,900,000	1,580,000	1,632,000	1,667,000	8,737,000	2,043,000	2,967,000	2,644,000	14,118,000	4,361,000	3,123,000	3,129,000	14,917,000	3,917,000	4,310,000		29,674,000	6,341,000	7,737,000		100,244,000	19,178,000			101,522,000	27,281,000	27,052,000	26,398,000	99,959,000	25,453,000	26,638,000	24,156,000	112,279,000	23,132,000	30,296,000	26,289,000	156,331,000	31,411,000	26,160,000
selling, general and administrative																						14,350,000	74,669,000	16,666,000	16,609,000	25,673,000	79,716,000	19,394,000	21,731,000	20,618,000	74,959,000	17,725,000	18,566,000	15,389,000	46,928,000	13,135,000	11,110,000
impairment of commitment asset																						1,521,000
gain on foreign currency translation																						-1,796,000	-1,913,000	-3,807,000							13,641,000
total expenses																						23,356,000	107,635,000	23,374,000	25,954,000	30,962,000	104,454,000	26,012,000	24,430,000	30,254,000	119,934,000	30,222,000	33,734,000	22,611,000	107,498,000	44,125,000
income from operations																						-7,121,000	-44,597,000	-8,779,000	-10,952,000	-13,514,000	-76,595,000	-21,543,000	-20,537,000	-26,789,000	-108,189,000	-28,179,000	-31,571,000	-19,602,000	67,260,000	118,229,000	-19,124,000		-344,655,000	-26,003,000	-24,051,000		-179,627,000	-38,266,000			-146,960,000	-44,762,000	-41,585,000	-36,437,000	-140,539,000	-35,487,000	-44,054,000	-33,933,000	-152,498,000	-32,773,000	-39,186,000	-38,001,000	-209,778,000	-42,540,000	-37,263,000
other income:
interest income																						133,000	997,000	220,000	255,000	318,000	501,000	144,000	55,000	106,000	293,000	65,000	58,000	55,000	85,000	28,000	26,000		18,000	2,000	3,000		9,000	1,000			7,000	2,000	1,000	1,000	18,000		1,000	1,000	40,000		2,000	15,000	70,000	16,000	3,000
interest expense on notes																						-1,071,000	-6,304,000	-4,126,000	-564,000	-593,000	-5,116,000	-993,000	-1,709,000	-1,794,000	-9,494,000	-2,310,000	-2,422,000	-2,706,000	-15,576,000	-4,166,000	-4,181,000		-21,231,000	-4,145,000	-4,131,000		-17,549,000	-5,424,000			-11,139,000
interest expense on promissory notes																						-1,259,000	-4,602,000	-1,162,000
other income																						-4,000	-926,000	-52,000	-17,000	-14,000	-437,000	10,000	30,000	31,000	13,000			14,000	-597,000	-27,000	-5,959,000		1,366,000	67,000	-10,000		1,679,000	7,898,000			-1,191,000	10,000	15,000	23,000	1,541,000	-2,651,000	13,347,000	1,382,000	-725,000	79,000	47,000	1,350,000	51,000	1,948,000	-1,257,000
total other income																						-2,201,000	-7,306,000	-1,591,000	-1,435,000	-1,369,000	-10,140,000	-2,625,000		-3,596,000	-9,093,000	-4,707,000	-3,768,000	3,278,000	58,404,000
income before benefit from income taxes																						-9,322,000		-10,370,000	-12,387,000	-14,883,000		-24,168,000	-22,435,000	-30,385,000																						-43,242,000	-36,578,000	-38,173,000	-170,560,000	-38,402,000	-44,480,000	-41,525,000	-220,104,000	-45,303,000	-42,251,000
benefit from income taxes																											240,000				51,000
net income																						-9,322,000	-51,903,000	-10,370,000	-12,387,000	-14,883,000	-86,975,000	-24,168,000	-22,675,000	-30,385,000	-117,333,000	-32,886,000	-35,339,000	-16,324,000	125,664,000	126,520,000	-29,959,000		-368,445,000	-31,857,000	-28,910,000		-198,382,000	-36,520,000			-169,366,000	-50,818,000	-46,124,000	-40,965,000	-160,804,000	-42,834,000	-36,578,000	-38,173,000	-170,560,000	-38,402,000	-44,480,000	-41,525,000	-220,104,000	-45,303,000	-42,251,000
net income per share																						-40	-270	-50	-70	-80	-600	-160	-160	-250	-1,130	-310	-350	-170	1,370	260	-70		-910	-80	-70		-510	-90			-940	-170	-160	-150	-1,320	-220	-230	-270	-1,500	-310	-370	-340	-2,070	-400	-370
shares used to compute basic and diluted net income per share																						212,467,000		199,906,000	188,054,000	187,434,000		153,597,000	140,054,000	120,911,000			99,864,000	95,744,000			455,305,000		406,165,000	405,199,000	401,018,000		385,229,000
facility financing obligation																									8,974,000	11,385,000	11,298,000	14,202,000	38,002,000	43,654,000	52,745,000	57,942,000	57,484,000	71,795,000	71,339,000	70,888,000	75,452,000	75,010,000	74,582,000	74,163,000	73,757,000	73,368,000	72,995,000		37,744,000	25,871,000	102,300,000	72,933,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2019 and 2018
gain on extinguishment of debt																							3,529,000	3,529,000			-765,000		772,000		-1,611,000				72,024,000
income before income tax expense																							-51,903,000				-86,735,000				-117,282,000
shares used to compute net income per share — basic and diluted																							195,584,000
right-of-use and other assets																								6,271,000	4,815,000	5,519,000
senior convertible notes - current																								2,520,000
deferred revenue - current																								32,212,000	32,370,000	32,384,000
recognized loss on purchase commitments - current																								3,593,000	11,649,000	9,057,000	6,657,000	16,081,000	13,191,000	15,859,000	12,131,000	12,480,000		6,984,000		8,340,000
credit facility																								38,798,000
accrued interest - promissory notes																								807,000
recognized loss on purchase commitments - long term																								85,858,000	81,978,000	85,344,000	91,642,000	84,362,000	88,346,000	96,694,000	97,585,000	99,769,000		95,062,000		63,229,000
deferred revenue - long term																								2,631,000	8,399,000	15,867,000
operating lease liabilities																								2,746,000	3,094,000	3,615,000
net revenue - commercial product sales																								6,402,000	6,065,000	5,076,000	17,276,000	4,387,000	3,753,000	3,402,000	9,192,000	1,981,000		1,196,000		573,000
revenue - collaborations and services																								8,193,000	8,937,000	12,372,000	10,583,000
revenue - other																													53,000		2,303,000
cost of revenue - collaborations and services																								1,836,000	2,139,000	1,537,000	1,077,000
note payable to related party																									71,981,000	72,036,000	72,089,000	72,143,000	72,196,000	72,247,000																		119,635,000	119,635,000	119,635,000	119,635,000	223,142,000	218,142,000	283,453,000	277,203,000	277,203,000	242,203,000	224,203,000	235,319,000	252,000,000	242,000,000	205,000,000	165,000,000	150,000,000	135,000,000	90,000,000	30,000,000
accrued interest - note payable to related party																									9,132,000	7,969,000	6,835,000	5,692,000	4,566,000	3,469,000
(gain) loss on foreign currency translation																									1,247,000	-1,935,000	-4,468,000	-728,000	-5,363,000				6,848,000		-3,433,000
interest expense on note payable to related party																									-1,109,000	-1,080,000	-4,323,000	-1,074,000	-1,046,000	-1,114,000																		-1,745,000	-1,689,000	-1,689,000	-10,883,000	-2,245,000	-3,028,000	-3,048,000	-10,249,000	-2,863,000	-2,509,000	-2,476,000	-5,679,000	-2,851,000	-2,523,000
loss on extinguishment of debt																												-712,000		-825,000			-830,000						-1,049,000	-1,049,000
deferred costs from commercial product sales																															405,000	543,000	500,000	472,000	309,000	279,000
deferred revenue																															3,038,000					2,014,000
deferred payments from collaborations - current																											36,885,000
deferred payments from collaborations - long term																											10,680,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2018 and 2017
property and equipment impairment																															203,000	92,000	111,000		1,259,000				140,412,000
gain on purchase commitments																											-10,000
change in fair value of warrant liability																															5,488,000	-1,289,000	147,000	6,629,000	5,369,000	13,185,000
shares used to compute basic net income per share																											144,136,000				104,245,000	104,703,000			92,053,000	478,137,000
shares used to compute diluted net income per share																											144,136,000				104,245,000	104,703,000			92,085,000	482,744,000
deferred payments from collaboration - current																												10,095,000	396,000	250,000	250,000	250,000		250,000
deferred payments from collaboration - long term																												2,638,000	2,403,000	437,000	500,000	563,000		687,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2018 and december 31, 2017
net revenue - collaborations																												82,000
income tax expense																													-240,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2018 and december 31, 2017
net revenue - collaboration																													87,000	63,000	250,000	62,000		63,000		161,781,000
total other																													-1,898,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2018 and december 31, 2017
loss on foreign currency translation																														2,984,000		3,684,000		1,545,000
receivable from sanofi																																			30,557,000
asset held for sale																																			16,730,000
note payable to principal stockholder																															79,666,000	79,666,000	79,666,000	49,521,000	49,521,000		49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000																													50,000,000
accrued interest - note payable to principal stockholder																															2,347,000	1,173,000		9,995,000
warrant liability																																	605,000	752,000	7,381,000	4,871,000	18,056,000
milestone rights liability and other liabilities																															7,201,000	7,202,000	7,202,000	7,202,000	8,845,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2017 and 2016
cost of revenue - collaboration
(gain) loss on purchase commitments																															-215,000				-2,265,000
interest expense on note payable to principal stockholder																															-3,782,000	-1,173,000	-721,000	-714,000	-2,901,000		-721,000		-2,894,000	-729,000	-721,000		-2,894,000	-729,000			-10,491,000
property and equipment - net																																27,374,000		28,482,000		46,825,000
deferred revenue - net																																3,021,000		1,844,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2017 and december 31, 2016
product costs - collaboration																																				22,742,000
gain on purchase commitment																																-215,000
income before benefit for income taxes																																-32,886,000	-35,339,000	-16,324,000	125,664,000				-368,445,000	-31,857,000	-28,910,000		-198,382,000	-36,520,000			-169,774,000	-50,818,000	-46,124,000	-40,965,000	-160,804,000
income tax benefit																																															408,000					-408,000
property and equipment—net																																	27,920,000																																																		66,511,000
liabilities and stockholders’ deficit
deferred revenue—net																																	2,592,000
deferred payments from collaboration—current																																	250,000
recognized loss on purchase commitments—current																																	9,926,000
accrued interest—note payable to principal stockholder
recognized loss on purchase commitments—long term																																	99,001,000
deferred payments from collaboration—long term																																	625,000
stockholders’ deficit:
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at june 30, 2017 and december 31, 2016
total stockholders’ deficit																																	-221,243,000	-198,725,000	-183,593,000	-238,687,000	-366,577,000	-373,464,000	-350,329,000	-124,569,000	-115,475,000		-73,770,000	-40,678,000			-30,713,000	-167,722,000	-152,357,000	-146,806,000	-110,679,000	-276,248,000	-244,375,000	-277,386,000	-313,652,000	-280,810,000	-245,382,000	-203,501,000	-185,532,000	-181,439,000	-137,662,000
total liabilities and stockholders’ deficit																																	79,374,000	85,185,000	107,063,000	96,131,000
net revenue—commercial product sales																																	1,548,000
net revenue—collaboration																																	63,000
revenue—other																																	552,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2017 and december 31, 2016
revenue - bulk insulin sales																																		1,750,000
deferred costs from collaboration																																					22,742,000
property and equipment — net																																			28,927,000		47,422,000	48,033,000	48,749,000	191,408,000	193,868,000	193,454,000	192,127,000	190,923,000	183,533,000	176,337,000	176,557,000	177,829,000	179,567,000	182,290,000	183,961,000	186,611,000	189,159,000	190,916,000	193,029,000	196,374,000	200,383,000	203,179,000	202,356,000	202,235,000	204,398,000	206,761,000	208,229,000	224,057,000	226,221,000	228,352,000	226,436,000	225,515,000	208,742,000	185,895,000	162,683,000	143,244,000	118,331,000	98,622,000	88,328,000	84,005,000	83,190,000	80,289,000	76,183,000
deferred revenue — net																																			3,419,000
deferred payments from collaboration																																			1,000,000	462,000	135,229,000	134,935,000	140,231,000	157,145,000	171,850,000	185,059,000	197,403,000
deferred sales from collaboration																																					26,882,000
accrued interest — note payable to principal stockholder																																			9,281,000
sanofi loan facility and loss share obligation																																				71,210,000		68,835,000	62,371,000	43,653,000	28,415,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or or outstanding at december 31, 2016 and 2015
revenue:
net revenue — collaboration																																			171,965,000
revenue — bulk insulin sales																																			898,000
total net revenue																																			174,758,000	162,354,000
costs of revenue — collaboration																																			32,971,000
note payable to our principal stockholder																																				49,521,000
senior convertible notes - long term																																				27,629,000
other liabilities																																				17,397,000	16,668,000	15,946,000	15,225,000	14,495,000	12,123,000	26,779,000	15,335,000	11,572,000	15,040,000	14,319,000	13,605,000	20,306,000																							24,000	24,000	24,000	24,000	24,000	24,000	24,000	24,000	29,000	36,000	43,000	48,000	76,000	58,000	130,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2016 and december 31, 2015
expense:
interest expense on note payable to our principal stockholder																																				-729,000
income before income tax benefit																																				126,520,000
receivables from collaboration																																						144,000	23,000	1,679,000	4,748,000	4,282,000	50,436,000
purchase commitment loss — current																																					20,986,000
sanofi loan facility and profit/loss share obligation																																					69,978,000
non-current purchase commitment loss																																					52,515,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2016 and december 31, 2015
total																																					139,434,000	93,272,000	126,412,000	278,014,000	352,551,000	360,022,000	394,439,000	386,818,000	236,306,000	224,553,000	258,646,000	287,608,000	212,429,000	215,196,000	251,314,000	210,331,000	240,392,000	251,420,000	199,553,000	224,014,000	228,358,000	254,752,000	277,256,000	305,149,000	239,557,000	243,255,000	247,397,000	288,655,000	267,126,000	275,711,000	282,459,000	331,632,000	399,248,000	465,402,000	543,443,000	364,136,000	418,237,000	482,567,000	539,737,000	149,702,000	144,579,000	191,991,000	228,371,000	260,024,000	114,817,000	141,757,000	163,483,000	181,797,000	110,778,000
revenue																																															35,000				50,000	35,000			93,000			50,000			93,000
operating expenses:
product manufacturing																																					3,704,000		67,442,000	8,115,000	5,691,000
total operating expenses																																					19,124,000		344,655,000	26,003,000	24,051,000		179,627,000	38,266,000			146,995,000	44,762,000	41,585,000	36,437,000	140,589,000	35,522,000	44,054,000	33,933,000	152,591,000	32,773,000	39,186,000	38,051,000	209,778,000	42,540,000	37,356,000
deferred product costs from collaboration																																						13,539,000	13,539,000	13,539,000	10,831,000
liabilities and stockholders’ equity
deferred product sales from collaboration																																						17,680,000	17,503,000	17,474,000	13,404,000	7,050,000
purchase commitment liabilities — current																																						12,927,000	12,475,000
net purchase commitments																																						55,605,000
stockholders’ equity
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2016 and december 31, 2015
inventory-current
state research and development credit exchange receivable — net of current portion																																											311,000			380,000	298,000	223,000	470,000	391,000	313,000				473,000	386,000	885,000	729,000	629,000	482,000	1,352,000	1,153,000	918,000	700,000	1,850,000	1,675,000	1,500,000	2,625,000	2,250,000	1,875,000	1,500,000	1,125,000	750,000	375,000	1,500,000	2,625,000	2,250,000	1,875,000	2,031,000		813,000
senior convertible notes — current
senior convertible notes — long term																																							27,613,000
purchase commitments — long term																																							53,692,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2015 and 2014
general and administrative																																							40,960,000	11,547,000	10,623,000		79,383,000	19,088,000			45,473,000	17,481,000	14,533,000	10,039,000	40,630,000	10,069,000	17,416,000	9,777,000	40,312,000	9,641,000	8,890,000	11,762,000	53,447,000	11,129,000	11,196,000
loss on purchase commitments																																							66,167,000
senior convertible notes-current																																									64,123,000
senior convertible notes-long term																																								27,607,000	35,713,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2015 and december 31, 2014
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2015 and december 31, 2014
deferred products costs from collaboration																																										6,251,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2015 and december 31, 2014
total stockholders’																																										-97,031,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2014 and 2013
state research and development tax credit exchange receivable – current																																												803,000
state research and development credit exchange receivable																																												260,000	463,000							293,000	658,000	565,000																										1,233,000	537,000	1,500,000		1,500,000
deferred up-front payment from collaboration agreement																																												150,000,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2014 and december 31, 2013
deficit accumulated during the development stage																																												-2,458,343,000	-2,421,824,000	-2,348,458,000	-2,296,402,000	-2,242,819,000	-2,192,001,000	-2,145,877,000	-2,104,912,000	-2,053,131,000	-2,010,298,000	-1,973,719,000	-1,935,546,000	-1,899,149,000	-1,860,747,000	-1,816,267,000	-1,774,742,000	-1,736,436,000	-1,691,133,000	-1,648,881,000	-1,604,182,000	-1,544,649,000	-1,499,094,000	-1,443,490,000	-1,384,078,000	-1,300,783,000	-1,232,286,000	-1,152,460,000	-1,081,039,000	-1,006,026,000	-932,979,000	-860,990,000	-787,849,000	-716,581,000	-655,611,000	-600,860,000	-557,301,000	-524,010,000	-492,280,000	-465,125,000	-442,963,000	-421,813,000	-401,625,000
in-process research and development costs
goodwill impairment
deemed dividend related to beneficial conversion feature of convertible preferred stock
accretion on redeemable preferred stock
net income applicable to common stockholders																																												-36,520,000			-169,366,000	-50,818,000	-46,124,000	-40,965,000	-160,804,000	-42,834,000	-36,578,000	-38,173,000	-170,560,000	-38,402,000	-44,480,000	-41,525,000	-220,104,000	-45,303,000	-42,251,000
shares used to compute basic and diluted net income per share applicable to common stockholders																																												394,163,000			180,855,000	296,386,000	284,044,000	280,058,000	121,817,000	190,534,000	159,859,000	143,154,000	113,672,000	122,130,000	121,708,000	121,057,000	106,534,000	113,528,000	113,116,000
share-based compensation liability																																													55,824,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2014 and december 31, 2013
total stockholders’ equity																																													-46,377,000	17,536,000																-100,942,000	-59,221,000	-2,405,000	-19,269,000	33,174,000	86,734,000	163,425,000	225,286,000	298,073,000	364,100,000	179,624,000	248,279,000	315,284,000	383,487,000	61,971,000	117,421,000	167,710,000	206,977,000	241,028,000	98,586,000	127,623,000	150,363,000	172,555,000	97,352,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2014 and december 31, 2013
state research and development credit exchange receivable — current																																																298,000	450,000	450,000	450,000					765,000		674,000	674,000				1,500,000				1,500,000				831,000				2,418,000	918,000		1,044,000	1,194,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2012 and 2013
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2013 and december 31, 2012
interest expense on senior convertible notes and facility financing obligation																																																-4,323,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2013 and december 31, 2012
interest expense on senior convertible notes																																																	-2,866,000	-2,863,000	-10,941,000	-2,859,000	-2,844,000	-2,575,000	-7,128,000	-2,845,000	-2,834,000	-2,413,000	-4,768,000	-1,876,000	-1,211,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2013 and december 31, 2012
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2011 and 2012
available-for-sale securities and certificate of deposit																																																				350,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2012 and december 31, 2011
available for sale securities and certificate of deposit																																																					350,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2012 and december 31, 2011
income taxes
available for sale securities																																																						350,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2012 and december 31, 2011
marketable securities																																																							515,000	513,000	497,000	549,000	4,370,000	117,000	2,414,000	2,488,000	2,475,000	2,649,000	2,639,000	3,115,000	18,844,000	63,651,000				51,875,000	67,599,000	102,824,000	116,924,000	7,007,000	23,800,000	56,700,000	89,597,000	113,166,000	22,884,000	44,958,000	11,546,000	5,000,000	3,887,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2010 and 2011
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2011 and december 31, 2010
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2011 and december 31, 2010
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2011 and december 31, 2010
commitments and contingencies stockholders’ deficit:
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2009 and 2010
state research and development credit exchange — current																																																												674,000				1,500,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2010 and december 31, 2009
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2010 and december 31, 2009
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2010 and december 31, 2009
commitments and contingencies stockholders’ equity
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2008 and 2009
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2009 and december 31, 2008
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2009 and december 31, 2008
stockholders’ equity:
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2009 and december 31, 2008
additional paid—in capital																																																																		1,475,290,000
commitments and contingencies stockholders’ equity:
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2007 and 2008
state research and development credit exchange																																																																								3,171,000	3,918,000	3,918,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2008 and december 31, 2007
undesignated preferred stock, 0.01 par value —— 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2008 and december 31, 2007
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2008 and december 31, 2007
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2006 and 2007
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2007 and december 31, 2006
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2007 and december 31, 2006
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2007 and december 31, 2006
deferred compensation																																																																																		1,373,000		1,373,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2005 and 2006
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2006 and december 31, 2005
state research and development credit exchange receivable current																																																																													1,043,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2006 and december 31, 2005
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2006 and december 31, 2005
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2004 and 2005
property, plant and equipment – net																																																																																71,387,000		67,999,000		66,223,000	66,235,000
state research and development credit exchange receivable – net of current portion																																																																																1,249,000		1,396,000		2,526,000
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at september 30, 2005 and december 31, 2004
property, plant and equipment — net																																																																																	68,353,000
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at june 30, 2005 and december 31, 2004
undesignated preferred stock, 0.01 par value-10,000,000 shares authorized; no shares issued or outstanding at march 31, 2005 and december 31, 2004
state r&d credit exchange receivable—current																																																																																			1,500,000
state r&d credit exchange receivable—net of current portion																																																																																			1,030,000
payable to stockholder
deferred compensation—current																																																																																			1,373,000
deferred compensation—net of current portion
series a redeemable convertible preferred stock, 0.01 par value—267,213 shares authorized, 267,212, issued and outstanding at december 31, 2003 and no shares authorized, issued and outstanding at december 31, 2004; aggregate liquidation value, 5,188 as of december 31, 2003
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at december 31, 2003 and 2004
series b convertible preferred stock, 0.01 par value—192,618 shares authorized, issued and outstanding at december 31, 2003 and no shares authorized, issued and outstanding at december 31, 2004; aggregate liquidation value, 15,000 at december 31, 2003
series c convertible preferred stock issuable
series c convertible preferred stock subscriptions receivable
notes receivable from stockholders
notes receivable from officers
deferred compensation – net of current portion
series a redeemable convertible preferred stock, 0.01 par value—267,213 shares authorized; no shares issued and outstanding at september 30, 2004; 267,212, issued and outstanding at december 31 2003
series b convertible preferred stock, 0.01 par value—192,618 shares authorized; no shares issued and outstanding at september 30, 2004; 192,618 shares issued and outstanding at december 31, 2003
series c convertible preferred stock issuable - .01 par value; 980,393 shares authorized; no shares issued and outstanding at september 30, 2004 and december 31, 2003, respectively
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized at september 30, 2004
note receivable from stockholders																																																																																				-1,490,000	-1,463,000
note receivable from officers
deferred compensation – current																																																																																					1,373,000
series a redeemable convertible preferred stock, 0.01 par value—267,213 shares authorized; 267,212, issued and outstanding at december 31 2003 and june 30, 2004, respectively; aggregate liquidation value, 5,188 as of december 31, 2003 and 5,248 as of june 30, 2004																																																																																					5,248,000
series b convertible preferred stock, 0.01 par value—192,618 shares authorized, issued and outstanding at december 31, 2003 and june 30, 2004, respectively; aggregate liquidation value, 15,000 at december 31, 2003 and june 30, 2004																																																																																					15,000,000
series c convertible preferred stock, .01 par value — 980,393 shares authorized; 980,392 shares issued and outstanding at june 30, 2004, aggregate liquidation value of 50,000 at june 30, 2004																																																																																					50,000,000

We provide you with 20 years of balance sheets for MannKind stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MannKind. Explore the full financial landscape of MannKind stock with our expertly curated balance sheets.

The information provided in this report about MannKind stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.